Press Releases April 19, 2026 08:00 PM

Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer

Lumexa Imaging strengthens leadership with Kyle Lynch appointment as Chief Growth Officer to accelerate expansion and growth.

By Jordan Park LMRI
Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer
LMRI

Lumexa Imaging has appointed Kyle Lynch as its new Chief Growth Officer to lead enterprise growth strategies including joint ventures, acquisitions, and new developments. Lynch will also enhance sales productivity and standardize performance metrics across the company's outpatient imaging centers. This move aims to capitalize on strong sector trends such as site-of-care migration and demand for advanced diagnostics, supporting Lumexa Imaging's continued geographic expansion and operational excellence.

Key Points

  • Appointment of Kyle Lynch as Chief Growth Officer to drive growth through acquisitions, joint ventures, and de novo developments.
  • Focus on enhancing sales productivity and establishing a data-driven commercial model across Lumexa's national footprint.
  • Strategic emphasis on capitalizing on outpatient imaging market trends, including site-of-care migration and fragmented provider landscape.

RALEIGH, N.C., April 20, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced the appointment of Kyle Lynch as its new Chief Growth Officer (CGO). Lynch joins the executive leadership team to lead the company’s enterprise growth strategy, with responsibility for expanding Lumexa Imaging’s platform through joint ventures, acquisitions, and de novo development.

In this role, Lynch will oversee the full growth lifecycle, including opportunity origination, transaction execution, and post-close value realization, with a focus on driving sustainable, profitable growth and maximizing return on invested capital. He will work closely with the CEO, CFO, Chief Strategy Officer, and operations leadership to ensure growth initiatives are tightly aligned with Lumexa Imaging’s clinical excellence, operational performance, and long-term financial objectives.

“Kyle brings a powerful combination of strategic insight, execution discipline, and commercial leadership,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “At a time when outpatient imaging is benefiting from strong secular tailwinds—including site-of-care migration, growing demand for advanced diagnostics, and a highly fragmented provider landscape, his track record of scaling growth platforms and delivering measurable results will be instrumental as we drive same-center performance and accelerate disciplined geographic expansion.”

Lynch will also lead Lumexa Imaging’s Sales Center of Excellence, advancing a scalable, data-driven commercial model across the enterprise. His focus will include enhancing sales productivity, standardizing performance metrics, and driving consistent referral growth and same-center performance across Lumexa Imaging’s national footprint.

“Lumexa Imaging has built a differentiated platform grounded in clinical excellence, operational rigor, and a strong patient and provider experience,” said Lynch. “I look forward to partnering with the leadership team to scale that platform, expand access to high-quality care, and deliver long-term value for patients, partners, and shareholders.”

Prior to joining Lumexa Imaging, Lynch served as SVP of Strategy and Development at SCA Health, where he led enterprise growth initiatives across a national healthcare services platform. He brings deep experience in building high-performing business development organizations, executing complex transactions, and driving growth strategies that translate into durable financial performance.

About Lumexa Imaging

Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and more than 185 outpatient imaging centers across 13 states, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our ability to drive future growth and execute on our goals, strategies and long-term objectives. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including but not limited to those risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (SEC). The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.

Media Contact
Melissa Weston
[email protected]

IR Contact
Sue Dooley
[email protected]


Risks

  • Execution risk in integrating acquisitions and joint ventures effectively across multiple states.
  • Potential challenges in sustaining same-center performance improvements and referral growth.
  • Market and regulatory risks that could impact the outpatient imaging industry and Lumexa's expansion plans.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026